TNFRSF9 and neoplasm: Use of agonists of CD137, a co-stimulatory molecule identified as a tumor endothelium marker by Seaman et al. (28), or of multivalent RNA aptamers binding CD137 have been shown to enhance anti-tumor CD8 T-cell-mediated immunity in mice (118–120).